Cited by 422Cardiac Ischemia and ReperfusionMetabolism, Diabetes, and CancerDiabetes Treatment and Management

Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling

Calvert, John W., Gundewar, Susheel, Jha, Saurabh, Greer, James J.M., Bestermann, William H., Tian, Rong, Lefer, David J.·2008·Diabetes

Abstract

OBJECTIVE: Clinical studies have reported that metformin reduces cardiovascular end points of type 2 diabetic subjects by actions that cannot solely be attributed to glucose-lowering effects. The therapeutic effects of metformin have been reported to be mediated by its activation of AMP-activated protein kinase (AMPK), a metabolite sensing protein kinase whose activation following myocardial ischemia has been suggested to be an endogenous protective signaling mechanism. We investigated the potential cardioprotective effects of a single, low-dose metformin treatment (i.e., 286-fold less than the maximum antihyperglycemic dose) in a murine model of myocardial ischemia-reperfusion (I/R) injury. RESEARCH DESIGN AND METHODS: Nondiabetic and diabetic (db/db) mice were subjected to transient myocardial ischemia for a period of 30 min followed by reperfusion. Metformin (125 microg/kg) or vehicle (saline) was administered either before ischemia or at the time of reperfusion. RESULTS: Administration of metformin before ischemia or at reperfusion decreased myocardial injury in both nondiabetic and diabetic mice. Importantly, metformin did not alter blood glucose levels. During early reperfusion, treatment with metformin augmented I/R-induced AMPK activation and significantly increased endothelial nitric oxide (eNOS) phosphorylation at residue serine 1177. CONCLUSIONS: These findings provide important information that myocardial AMPK activation by metformin following I/R sets into motion events, including eNOS activation, which ultimately lead to cardioprotection.

Integrity signals

Registry

Crossref · 10.2337/db07-1098

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Administration of metformin before ischemia or at reperfusion decreased myocardial injury in mice.

    “Administration of metformin before ischemia or at reperfusion decreased myocardial injury in mice [183].”

    From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [183]

  • Beneficial actions of metformin disappeared in cardiac-specific dominant-negative AMPKα2 transgenic mice or eNOS deficient mice.

    “The beneficial actions of metformin disappeared in cardiac-specific dominant-negative AMPKα2 transgenic mice or eNOS deficient mice [183].”

    From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [183]

  • During early reperfusion, treatment with metformin augmented I/R-induced AMPK activation and significantly increased eNOS phosphorylation at ser1177.

    “During early reperfusion, treatment with metformin augmented I/R-induced AMPK activation and significantly increased eNOS phosphorylation at ser1177 [183].”

    From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [183]

  • Cardioprotective effects of metformin on I/R are mediated by its activation of AMPK.

    “Recent studies suggest that the cardioprotective effects of metformin on I/R are mediated by its activation of AMPK.”

    From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [183]

  • Metformin failed to increase eNOS Ser1177 phosphorylation at reperfusion in AMPKα2 deficient mice.

    “Further, metformin failed to increase eNOS Ser1177 phosphorylation at reperfusion in AMPKα2 deficient mice [183].”

    From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [183]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Calvert, J. W., Gundewar, S., Jha, S., Greer, J. J. M., Bestermann, W. H., Tian, R., & Lefer, D. J.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Holston Valley Medical Center (US)
  • Brigham and Women's Hospital (US)
Venue
Diabetes
Published
2008-03-01
Volume
57
Issue
3
Pages
696-705
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2097668381
Cited by
422
References
46
Citations by year
2026: 10 · 2025: 12 · 2024: 13 · 2023: 20 · 2022: 29 · 2021: 20 · 2020: 36 · 2019: 25 · 2018: 24 · 2017: 29 · 2016: 27 · 2015: 27 · 2014: 26 · 2013: 24 · 2012: 28
FWCI
10.65
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (2 RO1 HL-060849-08, R01HL060849)
  • National Institute of Diabetes and Digestive and Kidney Diseases (F32DK077380)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
metformin, cardioprotection, myocardial ischemia-reperfusion injury, AMPK, endothelial nitric oxide synthase, diabetic cardiomyopathy, db/db mice, myocardial infarction
MeSH terms
Adenylate Kinase, Animals, Blood Glucose, Diabetes Mellitus, Gene Expression Regulation, Hypoglycemic Agents, Male, Metformin, Mice, Inbred C57BL, Mice, Transgenic, Multienzyme Complexes, Myocardial Infarction, Myocardium, Signal Transduction, Reperfusion Injury, Mice, Inbred NOD, Protein Serine-Threonine Kinases, Gene Deletion, Mice, Nitric Oxide Synthase Type III, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review